AMSBIO announce new additions and certifications for their market-leading range of clinical grade, chemically defined cryopreservation excipient solutions - STEM-CELLBANKER® and HSC-BANKER®.STEM-CELLBANKER® DMSO Free GMP grade is a new chemically defined freezing solution that does not contain DMSO as an anti-freezing agent. It was developed for customers who prefer not to use DMSO-containing cryopreservation solution due to the intended application of the samples. STEM-CELLBANKER® DMSO Free GMP grade is manufactured in compliance with JPN, EU, US, and PIC/S GMP…
Cambridge, UK, 01 September 2020: Mursla, a liquid biopsy company, has raised £410K from the UK Government’s Future Fund and existing investors. In addition, the organisation has secured a £40K COVID-19 grant from the Cambridgeshire Capital Grant Scheme.The funding will enable Mursla to finalise its work on its novel exosome-based liquid biopsy platform, ExoPhenoTM, with the aim of demonstrating how the platform can detect cancer signatures in plasma from solid tumours via exosomes.Exosomes are heterogeneous vesicles naturally released by all cells during their lives, especially…
Free COVID-19 risk assessment services are being offered by Bishop Simon. Bishop Simon is a Health, Safety and Biosafety Consultancy. Our Chartered Health and Safety Consultants have served, many scientific research organisations including the Medical Research Council and PSI (CRO). If you would like to tap into or expertise to carry out your COVID-19 risk assessment, review your current COVID-19 risk assessment or inspect your COVID measures then please contact us.
AMSBIO announce a new service designed to provide high-content cytometry data on cells and tissues enabling the automated analysis of fluorescent biomarkers on living cells or long-term stored biobanked cells and tissues.Leveraging the innovative ChipCytometry platform, AMSBIO is able to offer a complete workflow solution (products and services) for high-content cytometry on cells and tissues, from sample preparation and biobanking to biomarker analysis and data mining.The ChipCytometry platform operates by immobilizing cells in microfluidic chips, which are later stained…
The world's focus on healthcare and leadership has never been greater. COVID-19 has led us to place higher value on our health, and question what makes a good leader, in times of crisis and in securing our future.
The Life Sciences industry is somewhat unique, in that it has the power to influence both.
For those working in it, it is a challenging industry with high expectations. To manage a growing ageing population and continuously evolving healthcare needs, the life sciences industry needs innovative, high performing, happy and healthy leaders.
These leaders will be at the forefront…
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of Chair in September 2020.
Jackie is currently a Board Director at BenevolentAI and has over thirty years of experience in the bioscience research sector, working across academia and industry, including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline (GSK). BenevolentAI is a British-held company using AI to augment the research capabilities…
ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
Laboratory experiments have shown niclosamide stops…
Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020.
Group Financial Highlights
Reported revenue of £22.4m (HY19: £26.1m)1 down 13.9% (15.5% on a constant currency basis) largely due to impact of COVID-19 pandemic and a rapid reduction of academic research work in Q2 2020…